Abstract | OBJECTIVE: METHODS: Patients were recruited from a national multicenter prospective cohort with longitudinal serum samples and 28-joint count Disease Activity Scores (DAS28)/Health Assessment Questionnaire ( HAQ) measurement over 12 months. RESULTS:
Adalimumab (ADA) drug levels were significantly associated with ΔDAS28 (β 0.055, 95% CI 0.011-0.099; p = 0.014) and inversely with HAQ over 12 months (β -0.022, 95% CI -0.043 to -0.00063). Factors significantly associated with ADA drug levels were ADAb levels and body mass index. CONCLUSION:
Drug level testing in ADA-initiated PsA patients may be useful in determining treatment response/disability over 12 months.
|
Authors | Meghna Jani, Hector Chinoy, Anne Barton, for OUTPASS |
Journal | The Journal of rheumatology
(J Rheumatol)
Vol. 47
Issue 8
Pg. 1204-1208
(08 01 2020)
ISSN: 0315-162X [Print] Canada |
PMID | 31371650
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antirheumatic Agents
- Biomarkers, Pharmacological
- Tumor Necrosis Factor-alpha
|
Topics |
- Antirheumatic Agents
(therapeutic use)
- Arthritis, Psoriatic
(drug therapy)
- Biomarkers, Pharmacological
- Humans
- Prospective Studies
- Tumor Necrosis Factor-alpha
|